Course Description
On most studies, 80% of the enrollment occurs at 20% of sites, and 30% of sites fail to enroll a single subject. This is enormously wasteful to industry and is one key driver of spiraling development costs. When considering studies, sites must think through the clinical and operational barriers to enrollment and likewise those conducting the pre-site visits need to identify such barriers. Together the team must develop a plan to mitigate those barriers, and execute that plan.
Learning objectives
As senior director of global site intelligence for PPD, Clare is responsible for establishing and ensuring PPD as a leader in the field of investigator and site relations. She provides strategic direction to the global site intelligence staff and works globally to develop improved investigator site resources and to assist in the delivery of existing and future business. Grace joined PPD in 2006 as a project manager, specializing in oncology, and has risen through the ranks to her current leadership role.
Clare has over 16 years of clinical research experience. Prior to joining PPD, Clare worked as a study delivery leader with AstraZeneca, where she was responsible for the global delivery of key oncology studies. She also worked as a clinical development manager with Antisoma with responsibilities for several clinical development programs across a number of countries.
Clare received her bachelor’s degree in applied biochemistry and holds a doctorate in molecular oncology from the University of Manchester Institute of Science and Technology. She also sits on the Leadership Council of the Society of Clinical Research Sites (SCRS)
